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ABSTRACT
Unintentional weight loss in patients with pancreatic
cancer is highly prevalent and contributes to low thera-
peutic tolerance, reduced quality of life, and overall mor-
tality. Weight loss in pancreatic cancer can be due to
anorexia, malabsorption, and/or cachexia. Proper support-
ive care can stabilize or reverse weight loss in patients and
improve outcomes. We review the literature on supportive
care relevant to pancreatic cancer patients, and offer
evidence-based recommendations that include expert
nutritional assessment, counseling, supportive measures
to ensure adequate caloric intake, pancreatic enzyme
supplementation, nutritional supplement replacement,
orexigenic agents, and exercise. Pancreatic Cancer Action Net-
work-supported initiatives will spearhead the dissemination
and adoption of these best supportive care practices. The
Oncologist 2019;24:691–701
Implications for Practice: Weight loss in pancreatic cancer patients is endemic, as 85% of pancreatic cancer patients meet the
classic definition of cancer cachexia. Despite its significant prevalence and associated morbidity, there is no established
approach to this disease entity. It is believed that this is due to an important knowledge gap in understanding the underlying
biology and lack of optimal treatment approaches. This article reviews the literature regarding pancreas cancer-associated
weight loss and establishes a new framework from which to view this complex clinical problem. An improved approach and
understanding will help educate clinicians, improve clinical care, and provide more clarity for future clinical investigation.
PREVALENCE, CLASSIFICATION, AND SIGNIFICANCE
Weight loss (WL) is highly prevalent among patients with
pancreatic cancer (PC) [1, 2], as up to 85% of patients pre-
sent with WL at diagnosis [3]. Nearly 50% of those with
early-stage and locally advanced disease exhibit preopera-
tive WL [4], and 80% will develop progressive WL after
diagnosis. There are no approved medical treatments for
PC-associated weight loss (PAWL), and commonly used
orexigenic agents that stimulate appetite have no definite
benefit [5]. Therefore, progressive WL is one of the most
distressing and intractable features of PC [6].
Assessment of clinically significant WL in PC is complex
and hindered by a lack of standardized definitions and ther-
apeutic strategies [7–9]. The etiologies can be categorized as
due to anorexia, malabsorption, and/or cachexia (Fig. 1).
Clinically impactful WL in PC is frequently described as
cachexia, and classification systems for WL in cancer patients
are usually concerned with cancer cachexia. Cachexia is a
multifactorial syndrome characterized by progressive invol-
untary WL, loss of skeletal muscle mass with or without adi-
pose loss, and systemic inflammation [10]. Despite an
international consensus statement in 2011 regarding
cachexia [10], definitions of clinically important WL in cancer
patients remain unclear and heterogeneous [11].
WL in PC patients has predictive and prognostic implica-
tions. WL and cachexia predict poor outcomes in all PC
stages [4, 9, 12, 13]. Most patients with PC will die with
cachexia, and it’s estimated that ~30% will die of cachexia
[6, 9–11]. Decreased lean body mass and/or weight are pre-
dictors for toxicity [14, 15], mortality [16], postoperative
infections, length of hospitalization, and therapeutic inten-
sity [4, 9, 14, 16–21]. WL also correlates with shorter
progression-free survival (PFS) and overall survival (OS),
decreased response to chemotherapy, lower quality of life
(QOL), and declining performance status [3, 10]. In addition,
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obesity is a known risk factor for the development of PC
[22–25], and its presence at the time of diagnosis is an inde-
pendent predictor of survival [26]. Patients with low muscle
mass and high body mass index (BMI), a condition now
described as sarcopenic obesity, exhibit worse outcomes in
PC and many other diseases [6, 27, 28].
Optimal approaches to the diagnosis and management
of PC weight loss and cachexia are understudied and poorly
understood; however, nutritional intervention can improve
QOL and OS in advanced PC [29–31]. Recognizing and
treating malnutrition in advanced cancer early in the treat-
ment process is essential for improving outcomes [28, 32].
Furthermore, nutritional support in PC is complicated and
influenced by many factors including tumor response, dia-
betes, pain management, altered physiology, and other
comorbidities. In this review, we highlight the etiology,
assessment, and management of PAWL, provide best sup-
portive care recommendations based on current knowl-
edge (Fig. 2), and bring attention to the gaps.
SUPPORTIVE CARE WORKING GROUP CONSENSUS PROCESS
The Supportive Care Working Group (SCWG) was formed to
establish best supportive care practices across the Precision
Promise Consortium (PPC) and to help foster supportive care
research. The SCWG consists of scientists, physicians, and a
dietician with expertise in pancreatic cancer, nutrition,
exercise, cachexia, survivorship, and palliative care. The SCWG
compiled all evidence by searching PubMed articles (from
1977 to 2017) on PAWL and other relevant topics. Keywords
searched included weight loss, cachexia, anorexia, malabsorp-
tion, sarcopenia, pancreatic exocrine insufficiency,
malabsorption, pancreatic enzyme replacement therapy,
nutrition, and exercise. The group convened quarterly over an
18-month period and corresponded via teleconference
bimonthly. The group initially presented the evidence and con-
sensus to the PPC and Steering Committee (SC) in January
2017. The feedback was considered by the SCWG, integrated,
and presented back to the PPC and SC in August 2017. Addi-
tional feedback was integrated, and the final consensus is
presented here.
PATHOGENESIS (CAUSES OF PAWL)
We recommend categorizing PAWL into three causes:
anorexia, malabsorption/pancreatic exocrine insufficiency,
and cachexia/sarcopenia.
Anorexia
Anorexia is defined as loss of the desire to eat and is medi-
ated by the inability of the hypothalamus to respond to
energy deficit signals [28]. Pain, fatigue, depression, dysmo-
tility, constipation, chemosensory disturbances (changes in
smell and taste), vomiting, early satiety, and loss of appetite
all contribute to anorexia [10, 33–36]. An important aspect
of anorexia is the negative social impact including changes
in social encounters and relationships and a sense of help-
lessness, anxiety, and distress [37, 38]. Patients commonly
report distress related to dietary intake and gut symptoms
including difficulties with gas, belching, bloating, pain/dis-
comfort, and diarrhea leading to WL [39]. Additionally,
current chemotherapy regimens, including gemcitabine/nab-
paclitaxel [40], FOLIFIRINOX [41], and nanoliposomal
irinotecan/5FU [42], can cause nausea, vomiting, indigestion,
Figure 1. Definitions and classifications.
Abbreviation: PC, pancreatic cancer.
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diarrhea, and mouth sores [43] and thus contribute to lower
food intake and reduced nutrition.
Malabsorption/Pancreatic Exocrine Insufficiency
Pancreatic exocrine insufficiency (PEI), a common complica-
tion of PC, occurs when the pancreas is unable to maintain
normal digestive function (secretion of proteases, lipase, and
amylase), resulting in malabsorption and malnutrition. PEI
negatively impacts QOL [44, 45] and is associated with poor
survival [44–46]. Additionally, markers of malabsorption and
exocrine secretion impairment, such as fecal elastase-1, are
strongly correlated with poor survival in PC [46].
Symptoms of malabsorption include increased abdomi-
nal bloating or discomfort, excessive gas causing burping or
flatulence, indigestion, nausea, delayed gastric emptying/
early satiety, changes in bowel movements—increased fre-
quency, light color, floating, frothy, oily, and/or foul smell-
ing, and WL despite intake meeting estimated caloric needs.
Cachexia and Sarcopenia
Cachexia results from a complex interaction between tumor,
host, and therapy [34, 47] characterized by progressive wast-
ing of skeletal muscle mass and to a lesser extent adipose tis-
sue, occurring even before WL becomes apparent
(precachexia) [28, 48]. Preclinical models indicate that che-
motherapy and targeted agents can cause cachexia through
mitogen-activated protein kinase-dependent muscle atro-
phy, mitochondrial depletion, and muscle weakness leading
to disuse atrophy [49]. Despite the high prevalence and
potential for mortality, PC-associated cachexia is diagnosed
and treated in a minority of patients [5], as there is no estab-
lished treatment [50]. The stages of cachexia occur across a
spectrum starting with “precachexia” characterized by WL
<5%, then “cachexia” associated with systemic inflammation,
and ending with “refractory cachexia defined by a loss of
body reserves and rapidly deteriorating nutritional status
[10]. Not all patients will progress through all the stages, and
no predictive biomarkers have been identified to distinguish
patients who will progress [10].
WL is our current measure of cachexia. However,
advances in body composition assessment techniques indi-
cate skeletal muscle and adipose tissue may behave indepen-
dently during WL [51]. In obese patients with cancer, muscle
wasting is common and obscured [51]; 40% of PC patients
who were found overweight/obese at the time of diagnosis
exhibited muscle wasting [6]. Consequently, sarcopenic obe-
sity is linked to functional status, survival, chemotherapy tox-
icity, and poor outcomes following surgery [52, 53].
ASSESSMENT OF PAWL
The morbidity and mortality associated with PAWL compels
a comprehensive approach to its assessment and manage-
ment and should be tailored to each individual. We recom-
mend that all patients be screened for WL, receive clinical
and nutritional screening, be assessed for PEI, and receive
serum testing. Body composition measurements should be
considered in the research setting.
Screening for WL
It is important that clinicians assess and record the weight
of a patient at presentation and prior to diagnosis. A quick
review of WL history can illuminate the extent of PAWL.
Assessment of WL over time is one of the standardized
Figure 2. Clinically significant weight loss (see Table 1 for interpretation).
Abbreviations: CRP, c-reactive protein; GI, gastrointestinal; PEI, pancreatic exocrine insufficiency.
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diagnostic characteristics used to identify and document
adult malnutrition as recommended by the Academy of
Nutrition and Dietetics [54] and the American Society for
Parenteral and Enteral Nutrition. Any patient who demon-
strates moderate or severe WL and/or evidence of malnu-
trition or malnutrition risk by these criteria should be
directed to a registered dietitian for a more extensive
assessment and intervention as described below. The con-
sensus guidelines for interpretation of WL in adults is out-
lined in Table 1 [55].
Nutrition Screening and Clinical Assessment
Nutrition screening using a validated tool allows for identi-
fication and referral of at-risk patients to a registered dieti-
tian for complete nutrition assessment and intervention.
Screening should be completed on all patients before the
start of treatment and at regular intervals such as weekly
during radiotherapy, with each chemotherapy visit, and at
each surveillance visit [54, 56, 57].
Two nutritional screening tools have been vetted for
both inpatient and outpatient use: the malnutrition screen-
ing tool (MST) and the patient-generated subjective global
assessment (PG-SGA). The MST is a quick, valid, and reli-
able screening tool. It consists of two questions regarding
appetite and recent unintentional WL and has demon-
strated high sensitivity and specificity for identification of
individuals with or at risk of malnutrition [58]. The PG-SGA
is a valid and reliable assessment tool to identify and triage
malnourished patients with cancer in both the inpatient
and outpatient setting. The abridged PG-SGA forgoes the
physical examination used in the PG-SGA and is a practical,
informative, and valid tool for use in the outpatient oncol-
ogy setting for detecting malnutrition [59].
We recommend that patients are screened using one of
these tools; those deemed to be at risk for malnutrition
should then be referred to a registered dietitian for nutrition
assessment. The services of a registered dietitian are impor-
tant for the early identification of malnutrition and anticipa-
tion of nutritional impact on symptoms to help patients
maintain weight, stay on their intended treatment, and
maintain or improve QOL over the course of their disease.
A full nutrition assessment involves the following
elements: obtaining a food history, evaluation of anthropo-
metric measurements, review of medical history, biochemical
data, medical tests and procedures, and completion of a
nutrition-focused physical assessment [60]. Routine assess-
ment of food intake should include patient estimate of overall
food intake and 24-hour food recall [34]. An oncology-
focused assessment also involves reviewing the oncologic
treatment plan with the goal to determine current and antici-
pated nutrition issues [54, 57, 61]. This information is all
assimilated and used to formulate a plan to address existing
and potential influences on malnutrition.
Assessment for PEI
Although there are several tests to diagnose pancreatic exo-
crine insufficiency, their clinical application and use is vari-
able [62, 63]. Definitive identification of PEI in PC patients is
challenging; thus, PEI is usually a clinical diagnosis. Direct
measures of gastric and duodenal contents such as a
secretin-cerulein or secretin-pancreozymin tests are expen-
sive, invasive, and only available at specialized centers [64].
Other tests such as fecal fat test, fecal elastase, and coeffi-
cient of fat absorption (CFA) are more clinically available but
may be cumbersome [64–66]. Steatorrhea is classically
defined as at least 7 grams of fecal fat over 24 hours, in the
context of a 72-hour stool test while on 100 grams of fat daily
[67]. However, the stool collection and associated diet is
inconvenient and difficult for patients. Therefore, fecal elas-
tase measurements are often used to diagnose PEI [67–69].
Fecal elastase is less sensitive (72%) than CFA collection but
quite specific (90%). In PC patients, studies have shown a
prevalence of PEI varying from 50%–89% when defined by
low fecal elastase [46, 70, 71]. Expert opinion is that fecal
elastase is appropriate for unresectable patients but is insuf-
ficiently sensitive to detect mild-moderate PEI and unsuita-
ble for postpancreaticoduodenectomy patients [72].
Regardless, in standard PC care, these tests are not routinely
performed and the diagnosis is established clinically and
based on patients’ history and reported symptoms (uninten-
tional WL, change in stool, bloating after meals, etc.).
Patients should be clinically assessed for PEI upon diagnosis,
at the start of treatment, and on a regular basis throughout
the course of their treatment.
Serum Tests
There is no widely adopted serologic evaluation of patients
with PAWL. However, WL in cancer patients has been asso-
ciated with markers of inflammation, low levels of serum
testosterone in men, and vitamin deficiencies. A more com-
prehensive serologic evaluation of patients who present
with PAWL will likely improve supportive care.
Measuring serum inflammation in PC patients with a
Glasgow Prognostic Score (GPS) has shown prognostic
significance in several studies [73, 74], and is predictive of
surgical outcomes [75, 76]. The GPS and other markers of
inflammation are consistently associated with WL and
cachexia in cancer patients [77, 78]. GPS is usually scored
0, 1, or 2 by providing 1 point each for c-reactive protein
(CRP) >10 and Albumin <3.5. The GPS was recently studied
as a predictive factor for response to a novel therapeutic
in advanced PC [79]. Recent studies have also suggested
that CRP:Albumin ratio and neutrophil:lymphocyte ratio
also have prognostic validity [80, 81]. In routine practice,
this score could help identify patients at high risk for PAWL
and cachexia and could promote early intervention.
Male hypogonadism (MH) is a common complication in
advanced cancer [82] and prominent in cancer patients
Table 1. Interpretation of adult weight loss
Time
Weight loss for
moderate (nonsevere)
malnutrition
Weight loss for
severe malnutrition
1 week 1%–2% >2%
1 month 5% >5%
3 months 7.5% >7.5%
6 months 10% >10%
1 year 20% >20%
Adapted from [55] with permission.
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[83] with cachexia [84], occurring in more than 70% of these
patients [85]. Hypogonadism in cancer cachexia is associated
with decreased strength, poor nutritional status [86],
decreased performance status, depression, and decreased
survival [87, 88]. In a randomized study in cancer patients
with fatigue and MH, testosterone replacement improved
fatigue and performance status but not QOL [89]. Despite
the high prevalence of MH in cancer patients and associated
morbidity and mortality, there are no established guidelines
for the diagnosis and management of MH in this population
[90]. Consensus from the supportive care literature supports
the practical application of testosterone replacement in
symptomatic patients with MH [91].
There has been little published material regarding serum
assessment for vitamin and mineral deficiencies in patients
with PC. Most available literature is related to the post-
pancreatic resection setting [92] or in the broader topic of
PEI from all causes (chronic pancreatitis and cystic fibrosis
included) [62]. After resection, reported nutritional deficien-
cies include fat-soluble vitamins A, D, and E, vitamins B12
and B6, iron, zinc, selenium, biotin, and copper. None of
these can be considered diagnostic of malnutrition; however,
vitamin D deficiency has been reported in patients with PC
and may contribute to poor outcomes [93–95]. These find-
ings were concluded from retrospective analysis, and it is not
clear whether vitamin D supplementation improves out-
comes. We recommend that vitamin D deficiency should be
evaluated and supplemented per physician discretion.
Body Composition Measurements
Muscle volumes can be measured and sarcopenia diag-
nosed using several modalities: computed tomography
(CT) or magnetic resonance imaging (MRI); appendicular
skeletal muscle index obtained from dual energy x-ray
absorptiometry (DEXA); mid-upper-arm muscle area by
anthropometry; and whole-body fat-free mass index deter-
mined by bioimpedance analysis [10, 96–98]. As CT is com-
monly used in the diagnosis and treatment of PC, this
modality has been used to estimate sarcopenia radiograph-
ically by total psoas muscle area and radiodensity [96].
However, psoas muscle measurements do not reflect
whole-body muscle; thus, measurements of a whole-body
slice at the level of lumbar vertebrae are superior [99].
Morphometric analysis of diagnostic CT or MRI slices can
be used to calculate whole-body skeletal muscle and adi-
pose tissue, to assess muscle quality, and to detect pres-
ence of myosteatosis. Currently, this can be done using
dedicated commercial software such as Sliceomatic or Ima-
geJ. Skeletal muscle and adipose tissue can behave inde-
pendently during cancer progression and therapy [51, 100],
and there may be value in measuring these separate com-
partments in the research setting.
INTERVENTION FOR PAWL
Role of the Registered Dietitian
Dietitians play a central role in the successful management of
PAWL. Nutrition interventions for PAWL have improved
weight [30], QOL, and outcomes [29, 60, 101]. Dietitians can
provide essential dietary suggestions, identify PEI, and provide
recommendations for oral nutritional supplementation and
specialized nutrition support [102]. Dietitians may also pro-
vide more detailed advice on diet and pancreatic enzyme sup-
plementation for management of symptoms of PEI [103–106].
Pancreatic Enzyme Replacement Therapy
Pancreatic enzyme replacement therapy (PERT) has demon-
strated benefit for PC patients with PEI. Two randomized
controlled trials have evaluated the impact of PERT among
patients with PEI due to chronic pancreatitis or surgery.
These studies demonstrated an increase in fat absorption,
reduced stool frequency, improved stool consistency
[107–109], and symptom improvement [109]. A previous
double-blinded trial of 21 patients with unresectable PC
with obstructive jaundice in whom a biliary stent was
placed showed that patients randomized to PERT had
improved fat absorption and that WL was prevented com-
pared with those who were randomized to placebo [110].
In a retrospective, nonrandomized study of 66 unresect-
able PC patients receiving PERT with nutritional counseling
and palliative care or standard palliative care without PERT,
median survival of patients receiving PERT was longer than
that of those with standard palliative care (301 days
vs. 89 days) [111]. More recently, a randomized study
showed an increase in OS in patients randomized to taking
enzymes but did not reach statistical significance because of
a low enrollment rate [112]. Additionally, a prospective study
of unresectable patient receiving chemotherapy showed
improved changes in BMI and increased OS of patients who
received PERT compared with historical controls [113].
In a retrospective, nonrandomized study of 66 un-
resectable PC patients receiving PERT with nutritional
counseling and palliative care or standard palliative
care without PERT, median survival of patients
receiving PERT was longer than that of those with
standard palliative care (301 days vs. 89 days).
These clinical trials evaluating PERT used doses ranging
from 40,000 to 72,000 units of lipase for meals and
20,000–36,000 units of lipase per snack. The maximum effec-
tive dose is unclear, guidelines vary, and dosing recommenda-
tions for PC are not currently indicated on U.S. Food and Drug
Administration labels. Enzymes may be dosed based on body
weight, fat content of diet, clinical symptoms, degree of steat-
orrhea present, or general per meal/snack guidelines. The
recommended starting dose per meal is 500 lipase units per
kg; dosing should be modified as appropriate and should be
tailored to individuals as needed to reflect variations in meal
sizes and fat content of the diet, clinical symptoms, and the
degree of steatorrhea present. Dosages should not exceed
10,000 lipase units per kilogram body weight per day with a
maximum of 2,500 lipase units per kilogram per meal [64].
Patients should be instructed to take enzymes at the start of
the meal, and if taking multiple capsules, pills should be taken
© AlphaMed Press 2018www.TheOncologist.com
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at intervals at the start and then throughout the meal [114]. A
study using the Pancreatic Cancer Action Network’s Patient
Registry indicated that in patients taking PERT appropriately,
symptoms such as a feeling of indigestion andWL were signifi-
cantly improved [115].
Oral Nutrition Supplements
If patients show signs of deficiency, have prolonged inade-
quate intake, or have prolonged malabsorption, clinicians
should consider evaluation for deficiencies including
vitamins A, D, E, B12, and B6 as well as iron, zinc, selenium,
biotin, and copper. Supplements should be recommended
for replacement of known deficiencies in the diet or serum
levels. Serum values may be rechecked approximately
3 months after attempted repletion. For individuals with
inadequate intake of calories and/or protein, nutrition sup-
plement drinks may be recommended as part of the nutri-
tion care plan. Unfortunately, there have been few studies
investigating the vitamin deficiencies associated with PEI
and the benefit of oral nutrition supplements.
Specialized Nutrition Support
Specialized Nutrition Support (SNS) is the use of enteral or
parenteral nutrition. Both American and European guide-
lines for nutrition support recommend against routine use
of SNS for oncology patients [116, 117]. However SNS may
be necessary for patients with a dysfunction of the gastro-
intestinal tract such as gastric outlet obstruction or who
are severely malnourished and will be undergoing major
surgery [116–118]. If SNS is needed, enteral feeding is pre-
ferred because of lower risk of infections or other compli-
cations [119, 120]. In randomized studies, enteral feeding
has shown benefit over other forms of artificial nutrition in
patients following a pancreaticoduodenectomy [121].
Parenteral nutrition may improve weight [122] and main-
tain or improve performance status in selected patients, but
it is not routinely recommended. Careful evaluation should
be employed to identify those patients who would benefit
and to avoid indiscriminate use of artificial nutrition [123],
especially in cases of futile care and at end of life. Benefits
may be limited to the perioperative setting for patients who
are unable to tolerate oral nutrition, although there is a need
for more explicit criteria for use [121, 124].
Parenteral nutrition may improve weight and main-
tain or improve performance status in selected
patients, but it is not routinely recommended. Careful
evaluation should be employed to identify those
patients who would benefit and to avoid indiscrimi-
nate use of artificial nutrition, especially in cases of
futile care and at end of life.
Pharmacologic Interventions
Advances in the understanding of etiology of cachexia are
leading to pharmaceutical interventions aimed at targets
upstream (inhibiting systemic inflammation) or down-
stream (blocking catabolic pathways, stimulating anabolic
pathways, and reducing anorexia) [51].
Appetite stimulants are frequently prescribed for
patients with PAWL. Progestogens, such as megestrol acetate
and corticosteroids, are used as orexigenics [5, 125–127].
Their mechanism of action is also through inhibition of cyto-
kines (including interleukin-6 and tumor necrosis factor)
and de-repression of appetite. Anecdotal evidence suggests
cannabis improves appetite and food intake in patients with
PAWL, and synthetic delta-9-tetrahydrocannabinol, drona-
binol, is approved for use in acquired immunodeficiency
syndrome-related cachexia and emesis from chemotherapy.
However, insufficient data exist for prescribing cannabis for
cachexia [128], and a randomized study in advanced cancer
patients demonstrated superiority of megesterol acetate over
dronabinol [129]. Novel agents for appetite stimulation
include grehlin and grehlin mimetics, notably anamorelin, for
which significant increase in lean body mass was observed in
non-small cell lung cancer patients from two phase III trials
[130, 131].
Nonsteroidal anti-inflammatory (NSAID) agents, thalido-
mide, and omega-3 fatty acids modulate cytokine produc-
tion, thereby inhibiting inflammation. Previous studies of
these agents have not shown conclusive benefit, and their
routine use is not recommended. Agents targeting the
cytokine activin and the related muscle growth inhibitor
myostatin have also been evaluated, without report of benefit
to date (NCT01433263 and NCT01505530]. Newer therapies
include monoclonal antibodies against cytokines, including
interleukin-1 alpha (NCT03207724) [132]. Combination therapy
with NSAID, nutritional supplementation, dietary consultation,
and exercise showed benefit in a multicenter, randomized
phase II trial of patients with lung or pancreatic cancer, and
has now moved to phase III (MENAC, NCT02330926). Investi-
gations of many novel agents are ongoing; however, there are
currently no standard systemic therapies for PAWL or PC
cachexia [133].
Exercise
Physical activity (PA) and exercise could benefit patients
with PAWL. In cancer patients, PA has been shown to
improve health-related QOL and symptom burden. PA
resulted in improved treatment tolerance [134, 135] and is
associated with improved PFS and OS [136], suggesting
that the benefit of PA is not confined to disease-free
survivors.
Gradual resistance training and aerobic exercise can
also maintain and restore lean muscle mass [137]. In addi-
tion, prescribed exercise resulted in improved appetite and
general well-being in patients with advanced cancer receiv-
ing palliative care [138].
PA interventions have been deemed safe and feasible
in PC patients [139] and may attenuate cachexia by modu-
lating insulin sensitivity and inflammation [140–142]. Pro-
gressive postoperative exercise programs have also been
demonstrated to be feasible, resulting in lower levels of
fatigue and pain and improved perception of general
health [143]. In advanced disease, a home-based walking
intervention was associated with increased endurance
© AlphaMed Press 2018
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and improved symptom burden, with patients increasing
their average duration of moderate-intensity exercise
[144]. Given the potential for high symptom burden and
poor survival outcomes in PC, Groupe Cooperateur Multi-
disciplinaire en Oncologie has initiated a large randomized
trial of adapted physical activity in PC [139]. This study
will formally evaluate the benefits of aerobic and resis-
tance exercises on fatigue and health-related QOL, but
also investigate the effects of intervention on nutritional
status, insulin resistance, cancer treatment tolerance, and
survival.
One hundred fifty minutes per week of moderate-
intensity aerobic exercise and at least two sessions of
resistance training per week is the recommended physi-
cal activity for cancer patients and survivors [145–147].
The optimal form and duration of exercise is unclear, and
recommendations should be tailored to an individual’s
current fitness level, treatment-related late/long-term
toxicities, and comorbidities. Referral to physical therapy
or other exercise professionals to guide initiation and
engagement in physical activity may improve success and
thus should be considered for all patients [145–147].
Consensus Statement and Recommendation (Fig. 3)
Slowing WL in patients with PC should improve quality and
length of life both directly through maintaining function
and indirectly through enhancing treatment delivery and
response. In many cases, favorable response to therapy will
translate to overall improvement in symptoms and QOL.
We recommend all patients who have significant WL
and/or evidence of malnutrition be directed to a registered
dietician for a more extensive evaluation. As needed,
patients should be provided pancreatic enzyme
replacement therapy, correction of hormonal and micronu-
trient deficiencies, and oral nutrition supplementation.
Appetite stimulants should be considered. Patients
should be warned against inactivity, and moderate-
intensity exercise should be encouraged and supported.
Measures to optimize appetite, nutritional intake, micro-
nutrients, and anabolic potential, while reducing disuse
and catabolism, should be implemented and integrated
as part of treatment planning as thoughtfully and aggres-
sively as antitumor therapy.
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